Medications for Forgetfulness in Alzheimer's Disease
For forgetfulness associated with Alzheimer's disease, start with a cholinesterase inhibitor (donepezil, galantamine, or rivastigmine) as first-line therapy for mild to moderate disease, and add memantine for moderate to severe disease. 1, 2
First-Line Treatment: Cholinesterase Inhibitors
The evidence consistently supports cholinesterase inhibitors as standard first-line therapy for mild to moderate Alzheimer's disease 1, 2. All three agents show similar efficacy:
Donepezil
- Dosing: Start 5 mg daily, increase to 10 mg after 4-6 weeks
- Shows statistically significant improvements in cognition (ADAS-cog) and global function (CIBIC-plus), though cognitive improvements are small and may not reach clinical significance 2
- Most extensively studied with 34 reports from 24 distinct studies 2
- Important caveat: In mild cognitive impairment (pre-dementia), donepezil shows NO benefit and should not be used 2
Galantamine
- Dosing: 24-36 mg daily (titrate gradually)
- Demonstrates clinically significant improvements on global assessment (CIBIC-plus), though cognitive score improvements are statistically but not clinically significant 2
- May show particular benefit in patients with baseline ADAS-cog >30 and MMSE >12 2
Rivastigmine
- Dosing: Up to 12 mg daily oral, or transdermal patch
- Similar efficacy to other cholinesterase inhibitors 2
- Transdermal formulation causes fewer gastrointestinal side effects than oral formulation—consider this route if GI tolerability is a concern 3
Second-Line or Add-On: Memantine
Add memantine for moderate to severe Alzheimer's disease, either as monotherapy or combined with a cholinesterase inhibitor 2, 4:
- Dosing: Titrate to 20 mg daily
- NMDA receptor antagonist with different mechanism than cholinesterase inhibitors
- Shows improvements in cognition, global function, and activities of daily living in moderate to severe disease 2
- Better tolerability profile than cholinesterase inhibitors—adverse events include dizziness and agitation, but GI side effects are less prominent 2
- Evidence for combination therapy (memantine + cholinesterase inhibitor) is mixed, but this approach is reasonable for moderate disease 3, 4
Practical Algorithm by Disease Severity
Mild Alzheimer's Disease:
- Start any cholinesterase inhibitor (donepezil, galantamine, or rivastigmine)
- Choose based on tolerability preferences and dosing convenience
Moderate Alzheimer's Disease:
- Continue cholinesterase inhibitor AND add memantine 4
- OR start memantine as monotherapy if cholinesterase inhibitors not tolerated
Severe Alzheimer's Disease:
- Memantine monotherapy is appropriate 4
- Continue treatment until no meaningful social interactions remain
Critical Limitations and Caveats
Modest Clinical Benefits
The evidence shows statistically significant but clinically marginal improvements 2. While global assessment measures (CIBIC-plus) show clinically meaningful changes, pure cognitive scores (ADAS-cog) often do not reach the threshold for clinical importance (4-point change) 1, 2. This means patients and families should have realistic expectations—these medications stabilize or slow decline rather than dramatically improve function.
Side Effects to Monitor
- Cholinesterase inhibitors: Dose-related gastrointestinal effects (nausea, diarrhea, vomiting) are most common, with relative risks of 2.5-2.6 for nausea and diarrhea 1
- Muscle cramps can occur (particularly with galantamine, relative risk 9.62 in vascular dementia) 1
- Memantine: Generally better tolerated; watch for dizziness and agitation 2
Duration of Evidence
Most trials lasted only 6 months or less 2, so long-term efficacy beyond 6 months is uncertain. However, clinical practice supports continuing treatment as long as patients show stability or slower decline 4.
No Difference Between Cholinesterase Inhibitors
Direct comparison studies show no significant differences in efficacy between donepezil, galantamine, and rivastigmine 2. Choose based on:
- Dosing convenience (donepezil is once daily)
- Side effect profile (transdermal rivastigmine for GI sensitivity)
- Cost and availability